491000 — Livsmed Income Statement
0.000.00%
Last trade - 00:00- KR₩2tn
- KR₩2tn
- KR₩27bn
Annual income statement for Livsmed, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Revenue | ||
| Total Revenue | 17,267 | 27,121 |
| Cost of Revenue | ||
| Gross Profit | 9,479 | 14,547 |
| Selling / General / Administrative Expenses | ||
| Research And Development | ||
| Depreciation and Amortization | ||
| Unusual Expense / Income | ||
| Total Operating Expenses | 41,161 | 53,626 |
| Operating Profit | -23,894 | -26,504 |
| Gain / Loss on Sale of Assets | ||
| Total Net Non Operating Interest Income / Expense | ||
| Other Net Non Operating Costs | ||
| Net Income Before Taxes | -57,021 | -25,585 |
| Net Income After Taxes | -57,021 | -25,585 |
| Net Income Before Extraordinary Items | ||
| Net Income | -57,021 | -25,585 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||
| Income Available to Common Shareholders Including Extraordinary Items | ||
| Diluted Net Income | -57,021 | -25,585 |
| Diluted Weighted Average Shares | ||
| Basic EPS Including Extraordinary Items | ||
| Diluted EPS Including Extraordinary Items | ||
| Diluted EPS Excluding Extraordinary Items | ||
| Normalised Income Before Taxes | ||
| Normalised Income After Taxes | ||
| Normalised Income Available to Common Shareholders | ||
| Diluted Normalised EPS | -2,311 | -1,037 |
| Dividends per Share |